This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 9, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/19598, first published .
Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

Authors of this article:

Tjalf Ziemssen1 Author Orcid Image ;   Olaf Hoffmann2 Author Orcid Image ;   Luisa Klotz3 Author Orcid Image ;   Herbert Schreiber4 Author Orcid Image ;   Martin S Weber5, 6 Author Orcid Image ;   Benedict Rauser7 Author Orcid Image
Article Authors Cited by (15) Tweetations (4) Metrics

Journals

  1. Inojosa H, Ziemssen T. How to reduce the delay of diagnosing secondary progression in multiple sclerosis. Multiple Sclerosis Journal 2021;27(4):646 View
  2. Inojosa H, Rauser B, Ettle B, Ziemssen T. The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. Multiple Sclerosis and Related Disorders 2020;46:102523 View
  3. Inojosa H, Proschmann U, Akgün K, Ziemssen T. Should We Use Clinical Tools to Identify Disease Progression?. Frontiers in Neurology 2021;11 View
  4. Scott L. Siponimod: A Review in Secondary Progressive Multiple Sclerosis. CNS Drugs 2020;34(11):1191 View
  5. Torkildsen Ø, Linker R, Sesmero J, Fantaccini S, la Rosa R, Seze J, Duddy M, Chan A. Living With Secondary Progressive Multiple Sclerosis in Europe: Perspectives of Multiple Stakeholders. Neurodegenerative Disease Management 2021;11(1):9 View
  6. Ness N, Schriefer D, Haase R, Ziemssen T. Der Multiple Sclerosis Health Resource Utilization Survey. Fortschritte der Neurologie · Psychiatrie 2022;90(01/02):42 View
  7. Inojosa H, Akgün K, Haacke K, Ziemssen T. MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren. Fortschritte der Neurologie · Psychiatrie 2021;89(07/08):374 View
  8. Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño R, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research 2021;23(10):e29558 View
  9. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence 2022;Volume 16:1307 View
  10. Ziemssen T, Vandercappellen J, Jordan Mondragon V, Giovannoni G. MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression. Journal of Clinical Medicine 2022;11(15):4401 View
  11. Díaz-Villamarín X, Piñar-Morales R, Barrero-Hernández F, Antúnez-Rodríguez A, Cabeza-Barrera J, Morón-Romero R. Pharmacogenetics of siponimod: A systematic review. Biomedicine & Pharmacotherapy 2022;153:113536 View
  12. Krajnc N, Bsteh G, Berger T. Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. Frontiers in Neurology 2021;12 View
  13. Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler A, Lampl M, Linker R. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany. Frontiers in Neurology 2022;13 View
  14. Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Fuchs A, Wilke T, Ziemssen T. Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS). Journal of Clinical Medicine 2023;12(4):1441 View
  15. Sriwastava S, Elkhooly M, Amatya S, Shrestha K, Kagzi Y, Bhatia D, Gupta R, Jaiswal S, Lisak R. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis. Journal of Neuroimmunology 2024;390:578315 View